Evidence map›Paper›PMID 38123161›Full record

ArticleJournal of cachexia, sarcopenia and muscle2024

Inhibition of the skeletal muscle Lands cycle ameliorates weakness induced by physical inactivity.

Justin L Shahtout, Hiroaki Eshima, Patrick J Ferrara, J Alan Maschek, James E Cox, Micah J Drummond, Katsuhiko Funai

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Muscle-specific Keap1 deletion enhances force production but does not prevent inactivity-induced muscle atrophy in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Justin L ShahtoutDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Hiroaki EshimaDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Patrick J FerraraDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
J Alan MaschekDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
James E CoxDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Micah J DrummondDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Katsuhiko FunaiDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-3802-4756
University of Utah · USNagasaki International University · JP

Funding

Proteomics CoreU54DK110858 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Anna E Beaudin, JAMES Eric COX · 2016 to 2026
$8.6M
PE methylation in skeletal muscle energy efficiencyR01DK107397 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2017 to 2025
$3.8M
Regulation of macrophage metabolism in aged muscle during recoveryR01AG076075 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Micah J Drummond, Ryan M O'Connell · 2022 to 2026
$3.3M
LOOH-induced muscle atrophy with ageR01AG074535 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Micah J Drummond, Katsuhiko Funai · 2022 to 2026
$3.0M
Lands cycle and skeletal muscle insulin actionR01DK127979 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2022 to 2025
$1.9M
PE In Modulation of Energy Flux Through OxphosR01GM144613 · NIGMS · UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2021 to 2024
$1.6M
Agilent 6550 QTOF system for U of UtahS10OD016232 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2013 to 2013
$578k
Agilent 7200 GC/Q-TOF for the University of UtahS10OD021505 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2016 to 2016
$401k
NIA NIH HHS R01 AG074535NIA NIH HHS R01 AG076075NIDDK NIH HHS R01 DK107397NIDDK NIH HHS R01 DK127979NIDDK NIH HHS U54 DK110858NIGMS NIH HHS R01 GM144613NIH HHS AG074535NIH HHS AG076075NIH HHS DK107397NIH HHS DK127979NIH HHS GM144613NIH HHS S10 OD016232NIH HHS S10 OD021505ODCDC CDC HHS S10 OD016232ODCDC CDC HHS S10 OD021505
6 · The paper itself

Abstract

backgroundLipid hydroperoxides (LOOH) have been implicated in skeletal muscle atrophy with age and disuse. Lysophosphatidylcholine acyltransferase 3 (LPCAT3), an enzyme of the Lands cycle, conjugates a polyunsaturated fatty acyl chain to a lysophospholipid to form a polyunsaturated fatty acid containing phospholipid (PUFA-PL) molecule, providing substrates for LOOH propagation. Previous studies suggest that inhibition of the Lands cycle is an effective strategy to suppress LOOH. Mice with skeletal muscle-specific tamoxifen-inducible knockout of LPCAT3 (LPCAT3-MKO) were utilized to determine if muscle-specific attenuation of LOOH may alleviate muscle atrophy and weakness with disuse.

methodsLPCAT3-MKO and control mice underwent 7 days of sham or hindlimb unloading (HU model) to study muscle mass and force-generating capacity. LOOH was assessed by quantifying 4-hydroxynonenal (4-HNE)-conjugated peptides. Quantitative PCR and lipid mass spectrometry were used to validate LPCAT3 deletion.

resultsSeven days of HU was sufficient to induce muscle atrophy and weakness concomitant to a ~2-fold increase in 4-HNE (P = 0.0069). Deletion of LPCAT3 reversed HU-induced increase in muscle 4-HNE (P = 0.0256). No difference was found in body mass, body composition, or caloric intake between genotypes. The soleus (SOL) and plantaris (PLANT) muscles of the LPCAT3-MKO mice experienced ~15% and ~40% less atrophy than controls, respectively. (P = 0.0011 and P = 0.0265). Type I and IIa SOL myofibers experienced a ~40% decrease in cross sectional area (CSA), which was attenuated to only 15% in the LPCAT3-MKO mice (P = 0.0170 and P = 0.0411, respectively). Strikingly, SOL muscles were fully protected and extensor digitorum longus (EDL) muscles experienced a ~35% protection from HU-induced reduction in force-generating capacity in the LPCAT3-MKO mice compared with controls (P < 0.0001 for both muscles).

conclusionsOur findings demonstrate that attenuation of skeletal muscle lipid hydroperoxides is sufficient to restore its function, in particular a protection from reduction in muscle specific force. Our findings suggest muscle lipid peroxidation contributes to atrophy and weakness induced by disuse in mice.

Indexed as

Muscle, SkeletalMuscular Atrophy1-Acylglycerophosphocholine O-AcyltransferaseAnimalsLipidsMice1-Acylglycerophosphocholine O-AcyltransferaseLipidsLPCAT3 protein, mouseAtrophyDisuseLipid hydroperoxidesPhospholipidsSkeletal muscle

Identifiers

PMID38123161
PMCPMC10834354
OpenAlexW4390024723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.